JGC
MDGL icon

J. Goldman & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

J. Goldman & Co’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$917K – 667
2025
Q3 		$917K Buy
+2,000
New +$746K 0.02% 342
2023
Q2 		– Sell
-5,400
Closed -$1.31M – 449
2023
Q1 		$1.31M Buy
+5,400
New +$1.47M 0.05% 225
2022
Q4 		– Sell
-20,300
Closed -$1.32M – 441
2022
Q3 		$1.32M Buy
+20,300
New +$1.41M 0.06% 239

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Goldman & Co's MDGL Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 5,069 shares worth $2.72M. The stake represents 0.07% of the portfolio and ranks #293 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in MDGL as recently as Q3 2025.

J. Goldman & Co first reported a position in MDGL in Q2 2013 and has held it in 7 quarters since. The position peaked at $3.27M in Q1 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • J. Goldman & Co held 5,069 shares of Madrigal Pharmaceuticals worth $2.72M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.07% of J. Goldman & Co's portfolio in Q2 2026, its #293 holding.
  • J. Goldman & Co first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
  • J. Goldman & Co's Madrigal Pharmaceuticals position peaked at $3.27M in Q1 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.